Search results
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 20 hours agoThe FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna hopes to...
mRNA Is Promising A Breakthrough In Fighting Cancer
Benzinga via AOL· 4 days agoWhen it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 1 day agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 1 day ago...loss of $1.175 billion, or $3.07 a share, after net income of $79 million, or 19 cents a share,...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 24 hours agoMeanwhile, Moderna is expanding its efforts in cancer...with Merck on a cancer vaccine. The duo...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 1 day agoData readouts on mRNA-1083 and mRNA-1647 are expected before 2024-end. mRNA-1345, Moderna’s RSV ...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 1 day agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
InvestorPlace· 6 hours agoPharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes...
The CDC Took Out 148 Pages of Essential Information
Mercola· 17 hours agoPeople who receive a COVID-19 shot are at increased risk of myocarditis, or inflammation of the heart muscle,1 and pericarditis, which is inflammation of ...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Digital Journal· 1 day agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula ...